The report describes where and how the DMD gene is altered. Ask a genetic counselor to identify the exact variant, predicted reading frame, certainty, and which approved or investigational treatments are mutation-specific.
What this means in real life
The DMD gene is divided into numbered sections called exons. A deletion means genetic material is missing; a duplication means material is repeated; a point or small sequence variant changes one or a few DNA letters. These descriptions tell the laboratory where the change occurred, but the biological effect depends on whether the change disrupts the gene’s reading frame and prevents useful dystrophin from being made.
The often-cited “reading-frame rule” is helpful but not absolute. Out-of-frame variants are commonly associated with Duchenne and in-frame variants more often with Becker, yet exceptions occur. Symptoms, dystrophin prediction, variant classification and sometimes additional testing all matter. Exon numbers also matter for mutation-specific therapy, but a person is not automatically eligible for a drug simply because the report mentions the same exon number as the drug.
Ask for a one-page genetics summary that includes the genomic change, affected exons, predicted reading frame, inheritance implications and treatment relevance. That summary is useful for clinics, emergencies and trial prescreening, while the original report should still be retained.
A practical checklist
- ✓
Locate the exact HGVS variant or exon range on the report.
- ✓
Ask whether the change is predicted to be in-frame or out-of-frame and how reliable that prediction is.
- ✓
Confirm the laboratory’s classification and date of interpretation.
- ✓
Request formal assessment of exon-skipping amenability rather than using an online chart alone.
- ✓
Revisit interpretation when labels, trials or variant classifications change.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- What dystrophin production is this variant expected to allow?
- Are there known exceptions for this specific variant?
- Could RNA or protein studies clarify an uncertain result?
- Does this change affect carrier testing for relatives?
- Which approved and investigational approaches are relevant—and which are not?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.